7-hydroxy DPAT (hydrobromide)

7-hydroxy DPAT is a dopamine D3 receptor agonist. It selectively binds to the dopamine D3 over the D2, D1, and D4 receptors (Kis = 0.78, 61, 650, and 5,300 nM, respectively, in radioligand binding assays). 7-hydroxy DPAT increases calcium mobilization in HEK293 cells expressing the D3 receptor with an EC50 value of 13.5 nM in a FLIPR assay. It decreases the release of striatal dopamine and its metabolite 3,4-dihydroxyphenylacetic acid (DOPAC, Cay-24912) in rats when administered intraperitoneally at a dose of 0.25 mg/kg. 7-hydroxy DPAT (2 µg/µl for eight weeks, i.c.v.) reduces the loss of ipsilateral substantia nigra pars compacta (SNC) dopaminergic neurons in a rat model of Parkinson's disease induced by 6-OHDA (Cay-25330). It also decreases amphetamine-induced ipsilateral rotations and increases the number of steps reached with the contralateral paw in the staircase test in the same model.Formal Name: 7-(dipropylamino)-5,6,7,8-tetrahydro-2-naphthalenol, monohydrobromide. CAS Number: 76135-30-3. Molecular Formula: C16H25NO . HBr. Formula Weight: 328.3. Purity: >95%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMSO: soluble. SMILES: CCCN(CCC)C1CCC2=CC=C(O)C=C2C1.Br. InChi Code: InChI=1S/C16H25NO.BrH/c1-3-9-17(10-4-2)15-7-5-13-6-8-16(18)12-14(13)11-15,/h6,8,12,15,18H,3-5,7,9-11H2,1-2H3,1H. InChi Key: ODNDMTWHRYECKX-UHFFFAOYSA-N.